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Background:  Immunodeﬁciency  is  an  integral  aspect  of Down  syndrome,  as demonstrated  by  the  increased
susceptibility  to infection  of  affected.  Mortality  is still  higher  than  in general  population,  with  respiratory
infections  among  the  major  causes  of  death.  As more  people  with  Down  syndrome  are  living today
than  ever  before,  it is indispensable  to  develop  strategies  to  prevent  and  cure  the  associated  disorders.
Vaccination  is the  most  successful  instrument  of  preventive  medicine.  Special  seasonal  inﬂuenza  and
pneumococcal  vaccination  strategies  have  been  designed  for individuals  with  risk  conditions  of  all  ages.
Down  syndrome  individuals  are  not  included  in the  high-risk  categories.
Methods:  We enrolled  in our study  15 children  with  Down  syndrome  and  their  siblings, vaccinated  for the
ﬁrst  time  with  seasonal  inﬂuenza  vaccine  and  receiving  a  booster  dose  of a glyco-conjugated  pneumo-
coccal  vaccine.  We  compared  the  immunological  features  and  response  to  vaccination  measuring  serum
antibody titers  and  frequency  of speciﬁc  memory  B  cells.
Results:  We  conﬁrm  that  a  severe  reduction  of  switched  memory  B cells  is  always  associated  to Down  syn-
drome.  After  primary  vaccination  Down  syndrome  children  generate  signiﬁcantly  less  speciﬁc  switched
memory  B cells  than their  siblings.  The  response  to a booster  dose  of vaccine  is instead  comparable  in
both  groups.  The  production  of speciﬁc  antibodies  was  equally  effective  in  Down  syndrome  and  controls
both  after  primary  and  secondary  immunization.
Conclusions:  Down  syndrome  individuals  should  be considered  a high  risk  group,  because  of  their
increased  susceptibility  to infection  and  reduced  number  of  switched  memory  B cells.  Tailored  vacci-
nation  protocols  are  needed  in  order  to reduce  their  burden  of  infections  throughout  life.
©  2015  Published  by  Elsevier  Ltd.. Introduction
Down syndrome (DS) is the most frequent genetic condition
ccurring in 1/600 to 1/1000 live birth. Improved medical care and
he successful treatment of congenital heart defects have led to an
xtraordinary increase of life expectancy, from 10 years in 1960
o 60–65 years today [1]. As more people with DS are living today
han ever before, novel strategies to prevent and cure the associated
∗ Corresponding author at: Diagnostic Immunology Unit, Department of Oncohe-
atology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy.
el.: +39 066859 2647.
E-mail address: rita.carsetti@opbg.net (R. Carsetti).
ttp://dx.doi.org/10.1016/j.vaccine.2015.10.083
264-410X/© 2015 Published by Elsevier Ltd.disorders are needed. Mortality in DS is still higher than in gen-
eral population, with respiratory infections (RI) among the major
causes of death. Viruses such as inﬂuenza virus, respiratory syncy-
tial virus and parainﬂuenza viruses are frequently responsible for RI
[2,3] whereas Streptococcus pneumoniae is the major cause of pneu-
monia [4] in this group of patients. A study has demonstrated that
during the outbreak of the pandemic inﬂuenza A (H1N1) 2009 virus
in Mexico, likelihoods of hospitalization, intubation, and death
were respectively 16-fold, 8-fold, and 335-fold greater for DS than
non-DS infected individuals [5]. Although anatomic and functional
ear–nose–throat abnormalities [6] may  favor microbial coloniza-
tion in DS, the alterations of the immune response [7–14] play
an important role in the development and evolution of infections.
It has been suggested that the increased incidence of respiratory
6 ccine 33 (2015) 6689–6696
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Table 1
Clinical and demographic features of Down syndrome (DS) patients and controls.
DS patients Controls
N  (%) N (%)
Total 15 (50.00) 15 (50.00)
Male 8 (53.33) 8 (53.33)
Female 7 (43.75) 7 (43.75)
Age  (median) ys 6.58 7.75
Recurrent infections total 15/15 (100.00) 4/15 (26.66)
Infections of the superior respiratory tract 14/15 (93.33) 2/15 (13.33)
Pneumonia 7/15 (46.66) 2/15 (13.33)
Gastroenteritis 0/15 (0.00) 0/15 (0.00)
Urinary tract infections 0/15 (0.00) 1/15 (6.66)
Hospitalization for infections 8/15 (53.0) 1/15 (6.66)
Hospitalization for gastroenteritis 1/15 (6.66) 1/15 (6.66)
Hospitalization because of lower
respiratory tract infection
7/15 (46.66) 0/15 (0.00)
Hospitalization because of upper
respiratory tract infection
0/15 (0.00) 0/15 (0.00)
Congenital heart disease 10/15 (66.66) 1/15 (6.66)
Heart surgery 5/15 (33.33) 1/15 (6.66)
Thymectomy 1/15 (6.66) 0/15 (0.00)
Autoimmune diseases 3/15 (20.00) 0/15 (0.00)
Thyroiditis 3/15 (20.00) 0/15 (0.00)690 D. Valentini et al. / Va
nfections and autoimmune disorders in DS is reminiscent of com-
on  variable immunodeﬁciency [15].
Vaccination is the most successful instrument of preventive
edicine. Special seasonal inﬂuenza and pneumococcal vacci-
ation strategies have been designed for individuals with risk
onditions of all ages [16–18]. DS individuals are not included in
he high-risk categories [19,20].
Vaccines prevent infectious diseases by inducing the adap-
ive immune response to deliver two ﬁnal products: long-lived
lasma cells and switched memory B cells. Whereas long-lived
lasma cells constantly secrete antibodies thus maintaining a sta-
le level of pre-formed speciﬁc immunoglobulins in the serum,
witched memory are able to sense antigen and react to a sec-
ndary challenge by rapidly proliferating and producing antibodies
21]. In humans, along with switched memory B cells, another
ype of memory B cells, called IgM memory, ensure the ﬁrst-line
efense against infection by producing natural antibodies [22].
aintenance of memory B cells occurs through re-stimulation
ither by re-encounter with antigen or through TLR9 engagement
23,24].
We [25] and others [13,26] have recently shown that DS is
ssociated with a primary defect of the B-cell compartment, char-
cterized by a reduced number of all B-cell populations in the
eripheral blood and especially of switched memory B cells. We
ave also shown that memory B cells of DS children respond to
LR9 with increased proliferation and differentiation [25].
The low number of switched memory B cells in DS could be
xplained by their insufﬁcient production by the germinal center
r by their rapid exhaustion upon TLR9 engagement. The identiﬁca-
ion of the mechanisms responsible for the low number of switched
emory B cells is a pre-requisite for the development of tailored
accine protocols for the increasing DS populations.
The aim of our study was to investigate the ability of DS children
o generate switched memory B cells in response to vaccination.
. Materials and methods
.1. Study population
The study protocols and consent form were approved by the
thical Committee of Ospedale Pediatrico Bambino Gesù, Rome.
ritten informed consent was obtained from the families of the
ersons included in this study according to the principles expressed
n the Declaration of Helsinki.
We  enrolled in the study 15 children with DS and 15 con-
rols matched for age (±12 months) and sex. In order to minimize
he variables caused by environmental exposure to pathogens and
enetic factors other than trisomy 21, siblings of DS children were
ecruited as controls.
Inclusion criteria for DS children were: diagnosis of DS proven
y chromosome analysis, age between 3 and 12 years and no symp-
oms of infection at the time of blood sampling. Sibling of DS
hildren enrolled as controls had a similar age and no signs of
nfection.
Exclusion criteria for controls and DS children were: evidence of
alignancy, chemotherapy, post-chemotherapy and immunosup-
ressive treatment; contraindications to split inﬂuenza vaccine or
neumococcal vaccine administration.
The clinical history of the patients was obtained from medical
ecords and interviews by the physician. A standard questionnaire
or the occurrence of infections and any related hospitalization
as also administered. The medical records of all participants were
eviewed for frequency of infections, presence of congenital heart
isease, previous heart surgery, occurrence of autoimmune dis-
ases and hematologic disorders.Hematologic problems 2/15 (13.33) 0/15 (0.00)
Thrombocytopenia 1/15 (6.66) 0/15 (0.00)
Anemia 1/15 (6.66) 0/15 (0.00)
All DS patients and their siblings underwent venipuncture and
5 ml  EDTA-venous blood were collected for baseline immunolog-
ical evaluation (cell blood count, IgA, IgG and IgM concentration,
salivary IgA, T and B lymphocyte subsets) and baseline inﬂuenza
and pneumococcal antibody titers.
The response to a ﬁrst vaccine dose was  evaluated after a
single injection of the seasonal inﬂuenza vaccine (Inﬂexal V® (Cru-
cell) containing surface antigens of A/California/7/2009 (H1N1),
A/Victoria/361/2011 (H3N2) and B/Massachusetts/2/2012 virus
strains). Administration of a second vaccine dose was recom-
mended for all children, but it was impossible to obtain the consent
for a second blood withdrawal.
The recall response was  measured after a booster dose of anti-
pneumococcal glyco-conjugated vaccine (Prevenar 13-valent®,
Pﬁzer). We calculated the frequency of speciﬁc memory B cells and
the concentration of speciﬁc serum antibodies before vaccination
and two  weeks after.
2.2. Demographic characteristics and clinical history
The median age of DS children included in this study was  6.58
years (range 3.66–11), and the median age of the controls was
7.75 years (range 3.33–12.83). The sex distribution was the same
between DS children and controls (8 males and 7 females).
Table 1 summarizes the clinical ﬁndings in DS children and con-
trols. In particular all DS children had recurrent infections (100%)
more frequently of the upper respiratory tract (93.3%; 14/15) and
46.6% (7/15) of them suffered from recurrent pneumonia. Further-
more, 8 of the 15 DS children included in the study (53%) had
required hospitalization because of infection. Ten DS patients had
CHD (66.6%). Half of them had undergone heart surgery, because of
atrioventricular canal (two children) and ventricular septal defect
(three children). Only one child had been thymectomized. Patients
who did not require surgery had patent forame ovale (one child),
atrial septal defect (two children), ventricular septal defect (two
children). All DS children with CHD were hemodynamically stable
and did not need any therapy at the time of enrollment and during
the study.
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Three patients (20%) had autoimmune thyroiditis. Two  DS chil-
ren had hematologic disorders: one child had thrombocytopenia
nd one had iron deﬁciency anemia.
.3. Cell isolation and ﬂow cytometry analysis
Heparinized PBMCs were isolated by Ficoll PaqueTM Plus (Amer-
ham Pharmacia Biotech) density-gradient centrifugation, counted
nd stained with the appropriate combination of ﬂuorescent
abeled antibodies and analyzed by ﬂow cytometry [27,28]. Dead
ells were excluded from analysis by side/forward scatter gating.
ll analyses were performed on a FACSCanto (BD Biosciences) inter-
aced to PC FACSDiva software. A total of 500,000 events per sample
ere analyzed. Identiﬁcation of B- and T-cell subsets is described
n Supplementary materials and methods.
.4. Cell cultures
For polyclonal stimulation of memory B cells 1–2 × 106 PBMCs
ere cultured for 5 days with CpG as described before [27].
.5. ELISPOT
ELISPOT for total and pneumococcal polysaccharide speciﬁc
gM, IgA and IgG was performed as described before [27]. Antibody-
roducing cells against inﬂuenza were evaluated on plates coated
ith Inﬂexal V® (Crucell).
.6. Haemagglutination-inhibition (HAI) tests
Speciﬁc anti-inﬂuenza antibodies against the same antigens
ncluded in 2013/2014 inﬂuenza vaccines (A/California/7/2009,
/Texas/50/2012, and B/Massachusetts/2/2012) were measured by
AI tests, according to standard procedures [29]. The HAI titer was
he reciprocal of the highest dilution of serum that inhibited virus-
nduced haemagglutination.
Geometric mean titers (GMTs), seroprotection rate (the percent-
ge of vaccine recipients with a post-vaccination HAI titer of at least
:40) and seroconversion rate (the percentage of vaccine recipi-
nts with a ≥4-fold increase in serum HAI titers after vaccination)
ere calculated. A seroprotection rate exceeding 70%, a seroconver-
ion rate exceeding 40%, and a GMT  ratio (post-/pre-vaccination)
xceeding 2.5 were considered as cut-off levels of vaccine immuno-
enicity, according to the guidelines of the European Committee for
roprietary Medical Products (CPMP) [30].
.7. ELISA immunoassay
ELISA for the detection of total IgM, IgA and IgG and for anti-PnPS
erum IgG was performed as previously described [27].
.8. Statistical analysis
Comparison of lymphocyte population counts and total
mmunoglobulin levels was performed using the Mann Whitney U
est. ELISPOT results and level of speciﬁc immunoglobulin between
ontrols and DS children were statistically analyzed using the
ruskall–Wallis test followed by Dunn’s multiple comparison test.
HAI titers <10 were assigned an arbitrary value of 5. Compar-
son of GMTs before and after vaccination were carried out using
he Wilcoxon signed rank test. P values lower than 0.05 were con-
idered statistically signiﬁcant.
All statistical analyses were performed using the GraphPad
nStat Software.3 (2015) 6689–6696 6691
3. Results
3.1. Immunological features
We conﬁrmed that DS children have normal numbers of all T
cell populations with the exception of naïve CD4+ T cells that are
signiﬁcantly reduced, to roughly 70% of the control numbers (Fig. 1A
and B). As compared to their siblings, DS children have a signiﬁcant
reduction of total, mature-naïve and transitional B cells. The size
of each population is diminished to about 30% of controls (Fig. 1C).
The memory pool is the most dramatically affected: DS children
have ¼ of the memory B cells of their siblings. The two  populations
of memory B cells are not equally reduced: IgM memory B cells are
30% and switched memory B cells only 15% of the controls (Fig. 1D).
The immunological parameters are reported in Table 2.
Notwithstanding the contraction of the B-cell compartment,
serum immunoglobulin are normal, with the exception of IgM that
is around 40% less than in controls (Fig. 1 E–G). IgA in the saliva is
present in normal amounts (Fig. 1H).
3.2. Total memory function
We measured the function and size of the B-cell memory
repertoire in vitro by stimulating PBMCs with the TLR9 ligand
CpG [23,24]. Notwithstanding the signiﬁcant reduction of IgM and
switched memory B cells in the peripheral blood, the number of
total IgM-, IgA- and IgG-secreting cells was  comparable in DS and
non-DS children conﬁrming that memory B cells of DS individuals
have an increased ability to generate antibody-producing cells in
response to CpG in vitro [25]. In both controls and DS children the
total number of memory B cells able to generate antibody produc-
ing cells did not change signiﬁcantly after vaccination (Fig. 2A).
3.3. Response to the ﬁrst dose of inﬂuenza vaccine
We compared the ability of children with or without DS to
generate switched memory B cells in response to the ﬁrst dose
of vaccine. All children received one injection of the 2013–2014
seasonal inﬂuenza vaccine containing the surface antigens of the
A/California/7/2009 A/H1N1, A/Texas/50/2012 AH3N2 and B Mas-
sachusetts/2/2012 virus strains. None of the controls had been
previously vaccinated against inﬂuenza. Among DS children only
two had received the seasonal vaccine before (one in 2007 and the
other in 2004), thus with vaccines containing viral strains other
than those contained in the 2013–2014 Inﬂexal. We measured the
number of memory B cells speciﬁc for the inﬂuenza 2013–2014
vaccine by ELISPOT before (pre) and two weeks after (post) vacci-
nation.
The number of B cells producing IgM and IgA antibody able to
bind the inﬂuenza antigens contained in the vaccine was  compa-
rable in controls and DS children before immunization and did not
change signiﬁcantly after vaccination. Inﬂuenza-speciﬁc memory B
cells changed in response to vaccination. In the controls the median
number of B cells producing IgG against inﬂuenza vaccine antigens
increased from 75 cells/million in the pre-vaccination sample to
392 after vaccination. The increase, however, did not reach statisti-
cal signiﬁcance probably because of the low number of subjects. In
DS children the number of inﬂuenza speciﬁc memory B cells secret-
ing IgG was not inﬂuenced by vaccination (median values were 20
and 39, pre- and post-vaccination, respectively). For this reason,
in comparison to their siblings DS children had signiﬁcantly less
speciﬁc IgG producing cell, after vaccination (Fig. 2B).
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Fig. 1. T and B cells numbers in the peripheral blood of DS and control (CTR) children and immunoglobulin concentration. B and T cell populations were identiﬁed by ﬂow-
cytometry and calculated based on blood counts of the same day. (A, B) The box plots show the absolute numbers of the indicated T-cell populations. Statistical signiﬁcance
was  calculated by the Mann Whitney U test on the values measured in all 15 DS and 15 CTR children. (C, D) Box plots represent the absolute numbers of the indicated B-cell
populations in DS and CTR children. Mann Whitney U test was used to calculate signiﬁcance on the values measured in all 15 DS and 15 CTR children. (E–G) Total serum IgM,
IgG  and IgA levels in the serum of CTR and DS children were measured by ELISA. Statistical signiﬁcance was calculated by the Mann Whitney U test on the Ig levels of all 15
DS  and 15 CTR children. The concentration of serum IgM was signiﬁcantly different in DS children compared to CTR. (H) The concentration of IgA in the saliva, measured by
ELISA,  is comparable in CTR and DS children. Mann Whitney U test was used to calculate signiﬁcance on the values measured in all 15 DS and 15 CTR children. Open circles
represent the values measure in CTR and close circles in DS children.
D. Valentini et al. / Vaccine 33 (2015) 6689–6696 6693
Table  2
Immunological parameters.
DS median (range) CTR median (range) Mann–Whitney P-value*
Lymph 1725 (1100–3400) 2620 (1500–4500) 0.00596
B  cells 183 (100–400) 466 (200–700) <0.0001
Transitional 15 (2–94) 57 (12–118) 0.00072
Mature 107 (53–242) 327 (84–623) 0.0001
Memory B 16 (9–44) 54 (20–126) <0.0001
IgM  mem.  11 (5–35) 31 (10–87) 0.00014
Sw.  mem.  4 (2–10) 24 (10–42) 0.00116
T  cells (CD3) 1445 (796–2538) 1915 (1026–2941) 0.0056
CD4  424 (262–959) 663 (342–1376) 0.0136
CD8  370 (243–830) 423 (248–620) 0.3270
NK  134 (60–470) 202 (79–686) 0.1467
CD4-RA 80 (1–408) 145 (34–567) 0.0016
CD4-RO 67 (39–215) 88 (50–187) 0.4284
CD8-RA 63 (25–257) 71 (35–128) 0.9549
CD8-RO 35 (14–114) 22 (2–61) 0.1463
Serum  IgM 57.5 (37–106) 108.5 (38–187) 0.01078
Serum  IgA 134 (60–270) 131.5 (15–188) 0.65994
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* Statistically signiﬁcant values are shown in bold.
.4. Response to a glyco-conjugated pneumococcal vaccine
ooster dose
All DS children and the majority of the controls (13/15) had
eceived either two or three doses of anti-pneumococcal glyco-
onjugated vaccines before enrollment in our study. The last dose
ad been administered two to three years before booster.
As observed for inﬂuenza neither speciﬁc IgM nor IgA numbers
hanged after vaccination. The booster dose was able to signif-
cantly increase the number of speciﬁc memory B cells in DS
hildren (Fig. 2C). In the controls the increase of IgG producing
ells was not signiﬁcant probably because of a strong pre-existing
mmunity.
.5. Vaccine-induced antibodies
Speciﬁc antibodies in the serum are the most accepted bio-
ogical read-out of vaccine efﬁcacy. Although all controls and the
ajority of DS children had never been vaccinated before against
nﬂuenza, serum HAI antibody titers to H1N1 and H3N2 ≥ 1:40
ere detectable at T0 in controls (71% and 57% of individuals,
espectively) and DS children (50% and 36% of individuals, respec-
ively) (Table 3), indicating a previous natural exposure to these
iral strains. A different scenario was observed for the B strain for
hich none or limited seroprotection rate (14% of individuals) was
bserved in DS and controls, respectively. No speciﬁc HAI titers
gainst the current viral antigens were found at T0 in 2 DS chil-
ren who received a seasonal inﬂuenza vaccine in 2007 and 2008,
espectively.
Inﬂuenza vaccination increased signiﬁcantly the HAI antibody
iters to inﬂuenza antigens in both DS and control children (P-
alues ≤0.002). Although GMTs were higher in controls than in DS,
his group met  CPMP criteria, with seroconversion rates between
1% and 78%, and seroprotection rates between 71% and 93% for the
hree viral antigens (Table 3). Finally, the GMT  ratio exceeded 2.5
or the three antigens both in DS and controls.
IgG antibodies against pneumococcal polysaccharides were
resent in the serum before challenge at comparable concentra-
ions in DS and non-DS children and increased signiﬁcantly in both
roups (Fig. 3).. Discussion
Vaccination is the most effective and least expensive tool of
reventive medicine. Vaccines have been designed and vaccine933 (592–1558) 0.16758
63 (21.6–121.5) 0.409027778
schedules have been implemented with the aim of achieving
optimal protection for most of the population. There are, however,
individuals with special needs belonging to high risk cate-
gories because of medical conditions, occupational exposures, or
risk behaviors [31–33]. Targeted indications have been devel-
oped for these categories in order to increase vaccine induced
protection during the highest risk periods. Individuals with
DS are not included in high-risk groups notwithstanding their
increased susceptibility to infections, mostly of the respiratory
tract.
It is important to precisely identify the immunological impair-
ment typical of trisomy 21 in order to develop strategies for the
prevention of infection and its consequences in the growing DS
population.
To this aim we have compared a group of DS children to their sib-
lings of similar age and living in the same household. We  conﬁrmed
that the B-cell compartment is severely compromised in DS chil-
dren [25,26,34,35]. Transitional, mature-naïve and memory B cells
are all signiﬁcantly reduced in percentages and absolute numbers.
Whereas the numbers of transitional and mature-naïve B cells
are regulated by bone marrow production and space in the lym-
phoid organs, respectively, memory B cells are generated in the
periphery in response to T-independent and dependent cues. In
particular, switched memory B cells are produced by the germi-
nal center reaction to infection or vaccination and are the main
actors of recall responses. The low number of switched memory B
cells could be either explained by reduced production or increased
consumption.
Here we show that DS children vaccinated for the ﬁrst time
against inﬂuenza generate signiﬁcantly less switched memory B
cells speciﬁc for the vaccine than their siblings.
As all children had previously received a complete vaccination
cycle with a glyco-conjugated vaccine against S. pneumoniae, we
were able to evaluate the effectiveness of a secondary immune
response by administering a booster dose of glyco-conjugated vac-
cine. The secondary response was  successful, generating a number
of speciﬁc memory B cells similar to controls. DS children, however,
had a lower number of polysaccharide-speciﬁc switched memory
B cells in the pre-booster sample, although all children had com-
pleted the recommended vaccination schedule. This observation
may  reﬂect the exhaustion of memory B cells in DS individuals due
to their increased potential to terminally differentiate into plasma
cells [25].
The production of speciﬁc antibodies was equally effective both
after a primary and a secondary immunization.
6694 D. Valentini et al. / Vaccine 33 (2015) 6689–6696
Fig. 2. (A) The ability of memory B cells to generate antibody producing cells after CpG stimulation was  measured by ELISPOT in 15 CTR and 15 DS children. The number of
spots  obtained from 106 cells of CTR and DS children, secreting either IgM, IgA or IgG is indicated. No signiﬁcant differences between DS and CTR pre- and post-immunization
values  were found. (B) Numbers of memory B cells producing IgM, IgA and IgG antibodies speciﬁc for inﬂuenza in the peripheral blood of CTR and DS children were measured
by  ELISPOT before and after vaccination. (C) Numbers of memory B cells producing IgM, IgA and IgG antibodies speciﬁc for pneumococcal polysaccharides in the peripheral
blood  of CTR and DS children were measured by ELISPOT before and after vaccination. Kruskall–Wallis test followed by Dunn’s multiple comparison test were used to evaluate
signiﬁcant differences between all samples. Data are shown as scatter plots. The numbers of antibody secreting cells detected in the pre-vaccination samples are indicated
by  close circles for CTR children and by close triangles for DS children. The numbers of antibody secreting cells detected in the post-vaccination samples are indicated by
open  circles for CTR children and by open triangles for DS children.
Table 3
Antibody response to inﬂuenza vaccination in DS children and CTR measured by haemagglutination inhibition assay.
A/California/7/2009 (H1N1pdm) A/Texas/50/2012 (H3N2) B/Massachusetts/2/2012
T0 T1 T0 T1 T0 T1
Geometric mean titer
DS 32.8 452 17.2 131.2 5.8 44
CTR  36.2 609 22.1 262.4 7.8 138
Geometric mean titer ratio
DS 13.8 7.6 7.6
CTR  16.8 11.9 17.7
Seroconversion rate (%)
DS 78 78 71
CTR  78 86 86
Seroprotection rate (%)
DS 50 93 36 86 0 71
CTR  71 86 57 93 14 86
D. Valentini et al. / Vaccine 3
Fig. 3. Speciﬁc antibodies increase in the serum after vaccination. Serum IgG anti-
bodies directed against pneumococcal polysaccharides was  measured in the serum
by  ELISA before and after vaccination. Kruskall–Wallis test followed by Dunn’s mul-
tiple comparison test were used to calculate signiﬁcance on the values measured in
all  15 DS and 15 CTR children. Pre-vaccination values of serum IgG in CTR children are
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y the close triangles and the open triangles show the post-vaccination levels.
Thus, DS individuals in this study are perfectly able to respond
o vaccination with antibody secretion. They are, however, less able
o produce and maintain switched memory B cells.
Strengths of our study include examination of B cell functions
n two populations (DS and their siblings) similar for genetic and
nvironmental background with the exception of trisomy 21.
Limitations of the study are mainly associated with the small
ample size. The obtained results may  suffer from low power
nd lack of statistical signiﬁcance even when clinically signiﬁcant
esults were detected. Generalizability may  have been also affected
y the small sample size, although the enrollment was systemati-
ally conducted, and controls were matched among siblings.
A further limitation of our study is that we  compare a pri-
ary and secondary immunization not to the same vaccine but
o two different types of immunizing agents. Although from
he immunological point of view, the split inactivated inﬂuenza
accine is essentially a T-dependent vaccine as the pneumococ-
al glyco-conjugated preparation [36–38], further studies should
nvestigate the response to the ﬁrst and each subsequent dose of
lyco-conjugated pneumococcal vaccine and to a ﬁrst and second
nﬂuenza vaccine dose. It is also important to further address the
uestion of the duration of memory, a fundamental information
or the development of appropriate vaccine schedules, not only for
hildren but also for DS individuals of all ages.
In conclusion, DS individuals have a major defect in the number
nd generation of switched B memory cells and therefore should
e considered as a group at high risk for infections. Further stud-
es on large populations of DS children are necessary to evaluate
hether tailored vaccination schedules may  reduce the frequency
f infections and their complications thus improving the quality of
ife of DS individuals.
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